Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
01 Jan 2022
01 Jan 2022
Historique:
pubmed:
20
11
2021
medline:
24
12
2021
entrez:
19
11
2021
Statut:
ppublish
Résumé
The use of stereotactic body radiotherapy (SBRT) to treat ultra-central lung tumours remains more controversial than for peripheral and central tumours. Our objective was to assess toxicities, local control (LC) rate and survival data in patients with ultra-central lung tumours treated with SBRT. We conducted a retrospective and monocentric study about 74 patients with an ultra-central lung tumour, consecutively treated between 2012 and 2018. Ultra-central tumours were defined as tumours whose planning target volume overlapped one of the following organs at risk (OARs): the trachea, right and left main bronchi, intermediate bronchus, lobe bronchi, oesophagus, heart. Median follow-up was 25 months. Two patients (2.7%) showed Grade 3 toxicity. No Grade 4 or 5 toxicity was observed. 11% of patients experienced primary local relapse. LC rate was 96.7% at 1 year and 87.6% at 2 years. Median progression free survival was 12 months. Median overall survival was 31 months. SBRT for ultra-central tumours remains safe and effective as long as protecting organs at risk is treatment-planning priority. The present study is one of the rare to describe exclusively ultra-central tumours through real-life observational case reports. Globally, literature analysis reveals a large heterogeneity in ultra-central lung tumours definition, prescribed dose, number of fractions. In our study, patients treated with SBRT for ultra-central lung tumours experienced few Grade 3 toxicities (2.7%) and no Grade 4 or 5 toxicities, due to the highest compliance with dose constraints to OARs. LC remained efficient.
Identifiants
pubmed: 34797724
doi: 10.1259/bjr.20210533
pmc: PMC8722247
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20210533Références
Lung Cancer. 2020 Sep;147:45-48
pubmed: 32663723
J Clin Oncol. 2006 Oct 20;24(30):4833-9
pubmed: 17050868
Lung Cancer. 2015 Jul;89(1):50-6
pubmed: 25997421
Strahlenther Onkol. 2019 Aug;195(8):719-724
pubmed: 30689026
Cancers (Basel). 2020 Apr 05;12(4):
pubmed: 32260568
JAMA Oncol. 2019 May 1;5(5):737-739
pubmed: 30946430
Oncotarget. 2016 Apr 5;7(14):18135-45
pubmed: 26919113
Acta Oncol. 2014 May;53(5):590-6
pubmed: 23992110
Curr Oncol. 2017 Feb;24(1):e44-e49
pubmed: 28270731
Thorac Cancer. 2020 Mar;11(3):754-761
pubmed: 32012484
Pract Radiat Oncol. 2017 Sep - Oct;7(5):295-301
pubmed: 28596092
Int J Radiat Oncol Biol Phys. 2020 Jan 1;106(1):73-81
pubmed: 31499137
Cancer Sci. 2019 Nov;110(11):3553-3564
pubmed: 31464032
Cancer Treat Rev. 2008 Dec;34(8):719-27
pubmed: 18657910
Clin Lung Cancer. 2018 Sep;19(5):e803-e810
pubmed: 30007498
Pract Radiat Oncol. 2019 Mar;9(2):e196-e202
pubmed: 30496842
J Clin Oncol. 2019 May 20;37(15):1316-1325
pubmed: 30943123
J Thorac Oncol. 2016 Jul;11(7):1081-9
pubmed: 27013408
J Thorac Oncol. 2019 Aug;14(8):1332-1342
pubmed: 31075543
Clin Lung Cancer. 2018 Jul;19(4):e529-e532
pubmed: 29759332
Radiat Oncol. 2012 Sep 10;7:152
pubmed: 22963661
Semin Radiat Oncol. 2008 Oct;18(4):215-22
pubmed: 18725106
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):579-586
pubmed: 32188579
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Radiother Oncol. 2017 Jul;124(1):11-17
pubmed: 28687397
J Thorac Oncol. 2017 Sep;12(9):1442-1445
pubmed: 28576747
J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100
pubmed: 17603311
Br J Radiol. 2015 Jul;88(1051):20150036
pubmed: 25873481
Clin Lung Cancer. 2018 Mar;19(2):e241-e246
pubmed: 28941961
Radiat Oncol. 2018 Apr 2;13(1):57
pubmed: 29606150
Thorac Cancer. 2019 Jul;10(7):1567-1575
pubmed: 31187604